News and Announcements
Bioactive Annual Update 2016; New Compounds & Fractions Discovered, New Substance Pre-Screening Passed & Commercial Relationships Formed
- Published January 31, 2017 3:25PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Platform technology experts, Bioactive, continues to move forward with their capital raise along with achieving set targets during 2016:
- ‘Bioactive Therapeutics’, the Drug Discovery Division, has discovered new compounds and fractions to firmly establish a compound library within the key streams of inflammatory disorders and infectious diseases.
- ‘Bioactive Natural Health’, the Listed Medicine Division, has passed a rigorous TGA new substance pre-screening to proceed to full evaluation. Commercial relationships have been formed with some of the region’s largest companies and expect to be formalised to coincide with TGA approval in 2017.
- These opportunities collectively service the global market of 7 billion people. An investor exit is planned within 2 years.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
